CDK10 suppresses nucleic acid sensors-mediated antitumor immunity
Gaoshan Xu1,2, Fusheng Guo3,4, Chuan He1,2
1Department of Radiation and Medical Oncology, State Key Laboratory of Metabolism and Regulation in Complex Organisms, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Abstract:
Cancer immunotherapies have revolutionized cancer treatment, yet many patients fail to respond. Activating innate immunity offers a promising approach to enhance therapeutic efficacy, but the signaling kinases directly regulating this process to boost antitumor responses remain elusive. Here we conduct an in vivo kinome CRISPR screen and identify CDK10 as a key suppressor of tumor immune surveillance. Mechanistically, CDK10 phosphorylates DNMT1 and RAP80 to reduce the accumulation of double-stranded RNA and R-loops, which alleviates the activation of innate immune pathways mediated by MDA5 and cGAS. Kinase inhibitor screens identify NVP-AST487 and ponatinib as selective CDK10 inhibitors. Both genetic and pharmacological inhibition of CDK10 activates MDA5 and cGAS pathways, fostering an immunoactive tumor microenvironment that enhances cancer immunotherapy in multiple mouse tumor models. Clinically, low CDK10 expression in tumors correlates with better immunotherapy responses. These findings establish CDK10 as a pivotal modulator of tumor immunity and a potential therapeutic target.
Insights
CDK10 suppresses tumor immune surveillance by inhibiting innate immunity pathways. Inhibiting CDK10 activates these pathways, enhancing cancer immunotherapy and improving patient responses.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Cancer immunotherapies show promise but have limited efficacy in many patients.
- Activating innate immunity is a strategy to improve cancer treatment outcomes.
- Signaling kinases controlling innate immunity for antitumor responses are not fully understood.
Purpose of the Study:
- Identify novel kinases regulating tumor immune surveillance.
- Investigate the role of CDK10 in modulating the tumor immune microenvironment.
- Evaluate CDK10 inhibitors as a therapeutic strategy to enhance cancer immunotherapy.
Main Methods:
- Conducted an in vivo kinome CRISPR screen to identify key kinases.
- Utilized genetic and pharmacological inhibition of CDK10.
- Assessed the activation of innate immune pathways (MDA5, cGAS) and tumor microenvironment changes.
- Tested efficacy in multiple mouse tumor models and analyzed clinical data.
Main Results:
- Identified CDK10 as a critical suppressor of tumor immune surveillance.
- Demonstrated that CDK10 phosphorylates DNMT1 and RAP80, reducing dsRNA and R-loop accumulation.
- Showed that CDK10 inhibition activates MDA5 and cGAS pathways, enhancing anti-tumor immunity.
- Found that low CDK10 expression in tumors correlates with improved immunotherapy response.
Conclusions:
- CDK10 is a key regulator of tumor immunity and innate immune sensing.
- Targeting CDK10 can create an immunoactive tumor microenvironment, boosting immunotherapy efficacy.
- CDK10 represents a promising therapeutic target for enhancing cancer treatment.
More Related Videos
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
10:09Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Related Concept Videos
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Abnormal Proliferation
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Anaphase Promoting Complex
